Dr Lalchandani Labs survives on a one-time settlement. Auditors qualify the accounts.
A ₹61.08 lacs one-time settlement gain is the only thing standing between the company and an operational loss. Auditors flagged NPA classification and unpaid statutory dues.
— 2 earlier stories on Dr Lalchandani Labs Ltd. →What's new
- FY26 net profit collapsed to ₹6.35 lacs from ₹41.72 lacs the prior year.
- The company would have posted an operational loss without a ₹61.08 lacs one-time settlement gain.
- Auditors issued a qualified opinion citing NPA classification, loan defaults, and unpaid statutory dues.
Why this matters
Dr Lalchandani's reported profit is an accounting artifact, not an operating result. The company's accounts are classified as NPAs, it has defaulted on loans while holding cash, and has not paid statutory dues like Provident Fund and TDS since July 2024. For a firm valued at roughly ₹9 crore, these are not minor governance gaps.
What we're watching
- Whether the company clears the defaulted loan repayments and statutory dues.
- SEBI's response to the qualified audit opinion and NPA status.
- The impact on the company's ability to secure future financing.
The full read
Dr Lalchandani Labs reported a FY26 net profit of ₹6.35 lacs. Without a ₹61.08 lacs gain from a one-time settlement with lenders, the company would have lost money. The profit is a fiction of the settlement, not the core business. The auditors made this explicit by issuing a qualified opinion. They flagged that the company's accounts are classified as NPAs, that it has defaulted on loan repayments, and that it hasn't paid statutory dues like Provident Fund and TDS since July 2024. The company is a nano-cap valued at roughly ₹9 crore, but the audit trail points to fundamental operational and compliance failures. The reported profit masks a business that cannot sustain itself without exceptional items and has broken its obligations to both lenders and regulators.
Questions answered
- Why did Dr Lalchandani's net profit fall so sharply?
- Net profit fell to ₹6.35 lacs from ₹41.72 lacs the year before. The profit was only possible because of a ₹61.08 lacs one-time settlement gain from lenders; without it, the company would have recorded an operational loss.
- What did the auditors flag in their report?
- The statutory auditors issued a qualified opinion. They noted the company's accounts are classified as Non-Performing Assets (NPAs) and highlighted defaults on loan repayments and unpaid statutory dues, including Provident Fund and TDS, dating back to July 2024.
- Is the company in financial distress?
- The indicators are severe. Accounts are NPAs, loans are in default, and statutory payments are months overdue. The auditor's qualification and the reliance on a one-time gain to show any profit at all signal significant financial strain.
- What is the scale of the company?
- Dr Lalchandani Labs is a nano-cap entity with a market valuation of approximately ₹9 crore. Its total revenue was described as relatively stable year-on-year, but the profitability has deteriorated.
Story so far
All notes on DLCL →- 3 Jun 2026 · 9:31 PM IST Dr Lalchandani Labs survives on a one-time settlement. Auditors qualify the accounts.
- today Dr Lalchandani Labs posts profit only because lenders waived ₹61 lacs in debt
- today Lalchandani Labs auditors flag defaults despite cash reserves